- Home
- WHLR vs PCSA Comparison
WHLR vs PCSA Comparison
Compare WHLR & PCSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WHLR
- PCSA
- Stock Information
- Founded
- WHLR 2011
- PCSA 2011
- Country
- WHLR United States
- PCSA United States
- Employees
- WHLR N/A
- PCSA N/A
- Industry
- WHLR Real Estate Investment Trusts
- PCSA Biotechnology: Pharmaceutical Preparations
- Sector
- WHLR Real Estate
- PCSA Health Care
- Exchange
- WHLR Nasdaq
- PCSA Nasdaq
- Market Cap
- WHLR 3.0M
- PCSA 3.3M
- IPO Year
- WHLR 2012
- PCSA N/A
- Fundamental
- Price
- WHLR $1.80
- PCSA $0.19
- Analyst Decision
- WHLR
- PCSA Strong Buy
- Analyst Count
- WHLR 0
- PCSA 1
- Target Price
- WHLR N/A
- PCSA $1.00
- AVG Volume (30 Days)
- WHLR 1.6M
- PCSA 4.5M
- Earning Date
- WHLR 08-05-2025
- PCSA 10-29-2025
- Dividend Yield
- WHLR N/A
- PCSA N/A
- EPS Growth
- WHLR N/A
- PCSA N/A
- EPS
- WHLR N/A
- PCSA N/A
- Revenue
- WHLR $102,799,000.00
- PCSA N/A
- Revenue This Year
- WHLR N/A
- PCSA N/A
- Revenue Next Year
- WHLR N/A
- PCSA N/A
- P/E Ratio
- WHLR N/A
- PCSA N/A
- Revenue Growth
- WHLR N/A
- PCSA N/A
- 52 Week Low
- WHLR $1.50
- PCSA $0.15
- 52 Week High
- WHLR $10,458.00
- PCSA $1.50
- Technical
- Relative Strength Index (RSI)
- WHLR 31.68
- PCSA 35.68
- Support Level
- WHLR $1.59
- PCSA $0.18
- Resistance Level
- WHLR $2.24
- PCSA $0.23
- Average True Range (ATR)
- WHLR 0.29
- PCSA 0.01
- MACD
- WHLR 0.09
- PCSA -0.00
- Stochastic Oscillator
- WHLR 30.30
- PCSA 13.67
About WHLR Wheeler Real Estate Investment Trust Inc.
Wheeler Real Estate Investment Trust Inc is a self-managed commercial real estate investment company. It owns, leases, and operates income-producing retail properties with a primary focus on grocery-anchored centers. The company's properties include Alex City Marketplace in Alexander City, Alabama; Bryan Station in Lexington, Kentucky; Cardinal Plaza in Henderson, North Carolina; Clover Plaza in Clover, South Carolina; Winslow Plaza in Sicklerville, New Jersey and many more.
About PCSA Processa Pharmaceuticals Inc.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).